Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Brincidofovir in Adult Allogeneic HCT Recipients With Adenovirus Viremia
NCT03532035Phase 2Withdrawn
- Sponsor
- Chimerix Inc.
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in adenovirus infection comparing Brincidofovir (BCV) with Standard of Care (2 arms). Primary endpoints: Plasma area under the curve of BCV at 15 days, Plasma Cmax of BCV at 15 days and 1 more. Planned start Dec 2018; status: withdrawn.
02
Drugs
brincidofovir
03
Conditions
adenovirus infection
Beyond the preview
Go deeper on NCT03532035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532035.